View the latest news & insights from Artera

March 21, 2023
Artera Launches with $90 Million in Funding to Personalize Cancer Therapy With Multimodal AI

Artera, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, launched publicly today with $90M in funding.

February 27, 2023
Our very own Tim Showalter presented our science at Biomarkers 2023 in Manchester, UK from February 27-28.

Pathology-Based Deep Learning Tools to Personalize Treatment Decisions:
ArteraAI Prostate Test Development & Validation

Presented by: Tim Showalter, MD, MPH (Monday, February 27, 2023 at 9:45 AM EST)

February 18, 2023
MMAI Model More Accurately Predicts Outcomes of High-Risk Prostate Cancer

Jessica Nye from Cancer Therapy Advisor discusses key findings, presented by Daniel Spratt, MD at ASCO GU 2023, demonstrating that Artera’s prognostic MMAI biomarker can more accurately estimate long-term outcomes compared to standard clinicopathologic markers for patients with high-risk prostate cancer.

February 17, 2023
Dr. Spratt Highlights the Validation of an MMAI Prognostic Biomarker for Prostate Cancer

Urology Times features a video of Daniel Spratt, MD discussing results demonstrating successful validation of Artera’s MMAI prognostic biomarker in high-risk prostate cancer.

February 16, 2023
Multimodal AI Biomarker May Help Personalize Decision-Making in High-Risk Prostate Cancer

Mark Leiser from HemOnc Today discusses results from Artera’s prognostic MMAI model that were presented by Daniel Spratt, MD at ASCO GU 2023. The article includes a perspective from Eric Horwitz, MD, FABS, FASTRO.

February 16, 2023
Artera Announces Positive Results Around Its Multimodal Artificial Intelligence (MMAI) Prognostic Biomarker
February 16, 2023
Our science was presented at the 2023 ASCO Genitourinary Cancers Symposium in San Francisco from February 16-18.

Patient-Level Data Meta-Analysis of a Multi-Modal Artificial Intelligence (MMAI) Prognostic Biomarker in High-Risk Prostate Cancer: Results From Six NRG/RTOG Phase III
Randomized Trials

Presented by: Daniel Spratt, MD (Thursday, February 16, 2023 at 8:42 AM PST)

February 16, 2023
Artera Announces Positive Results Around Its Multimodal Artificial Intelligence (MMAI) Prognostic Biomarker
February 13, 2023
How AI can support the American Cancer Society’s IMPACT Initiative

Andre Esteva, Co-founder and CEO of Artera, discusses how AI can support the ACS’ IMPACT initiative and other possibilities in the healthcare industry.

October 24, 2022
Our science was presented at the 2022 ASTRO Annual Meeting in San Antonio from October 23-26.

Presidential Symposium: The State of the Art in Digital Pathology and AI: Progress in Prostate Cancer
Presented by: Osama Mohamad, MD (Sunday, October 23, 2022 at 12:15 PM)
UroToday Article

Plenary Session: Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital Histopathology
Presented by: Jonathan D. Tward, MD, PhD, FASTRO (Monday, October 24, 2022 at 1:46 PM)
UroToday Article

Want more information about Artera?
Use our contact form to connect with the team.